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Abstract: Oil-in-water nanoemulsions (NEs) are considered a suitable nanotechnological approach to
improve the eye-related bioavailability of lipophilic drugs. The potential of cationic NEs is prominent
due to the electrostatic interaction that occurs between the positively charged droplets with the
negatively charged mucins present in the tear film. This interaction offers prolonged NEs residence
at the ocular surface, increasing the drug absorption. Triamcinolone acetonide (TA) is one of the first
pharmacologic strategies applied as an intravitreal injection in the treatment of age-related macular
degeneration (AMD). Newly synthesized quaternary derivatives of 1,4-diazabicyclo[2.2.2]octane
(DABCO) and quinuclidine surfactants have been screened with the purpose to select the best
compound to formulate long-term stable NEs that combine the best physicochemical properties for
the loading of TA intended for ocular administration.
Keywords: cationic nanoemulsions; DABCO surfactants; quinuclidine surfactants; ocular adminis-
tration; triamcinolone acetonide
1. Introduction
Oil-in-water nanoemulsions (NEs) are one of the methodologies for preparing formu-
lations to improve the ocular bioavailability of lipophilic drugs [1,2]. Among NEs, cationic
NEs present prominent potential due to the electrostatic interactions occurring between the
positively charged eye-droplets with the negatively charged mucins expressed at ocular
surface epithelia and are responsible for the tear film maintenance [3,4]. This electrostatic
interaction offers prolonged NEs residence time at the ocular surface increasing the drug
absorption [5]. Topical instillations of eye-drops are the common treatment for ophthalmic
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diseases. However, in the treatment of age-related macular degeneration (AMD), one of
the first pharmacologic drugs, triamcinolone acetonide (TA), is only applied as intravitreal
injections. TA presents important effects in the stabilization of the blood-retinal barrier and
in the management of inflammation, and also exhibits relevant antiangiogenic and anti-
fibrotic properties [6]. TA is a synthetic corticosteroid that, besides being well tolerated by
ocular tissues, remains pharmacologically active for months after intravitreal injection, and
is thus used in the treatment of several ocular diseases [6–8]. TA is also used to treat skin
inflammatory diseases, and its formulation in transfersomes demonstrated a prolonged
anti-inflammatory action in comparison to conventional formulations [9]. Conventional
eye-drops are well accepted by patients; nevertheless, these formulations have some techni-
cal issues, namely, stability, solubility and low bioavailability (due to small residence time
at the ocular surfaces) leading to a loss of about 90% of the administered drug as a result of
blinking and solution drainage [8,10,11]. Ocular bioavailability of lipophilic drugs, such as
TA, can be improved by formulating them in oil-in-water (o/w) NEs, in which the drug is
solubilized at the innermost oil phase or at the o/w interface of the NEs [12]. The NE oil
droplets have a nanometric size which leads to a large surface area that is an advantage
to the drug diffusion and absorption [13]. The blinking and the composition of the tear
are responsible for the NEs breakdown after administration. So, after NEs breakdown,
the drug molecules are released and the oily phase of the NEs mixes with the tear film
lipid layer [5]. Other advantages of NEs include enhanced ocular retention associated with
extended effect duration, sustained drug-release, reduced systemic side-effects and, as
NEs are able to interact with the tear film lipid layer, they can stay for a longer time in the
conjunctival sac, acting as a drug depot [14–16]. Additionally, the NE droplet surface can
be functionalized with cationic lipids or surfactants or polymers to form positively charged
droplets, enhancing residence time [5].
Among the wide range of environmentally friend, cleavable, less toxic cationic
and green cationic surfactants containing natural moiety of particular interest are the
quaternary derivatives of 1,4-diazabicyclo[2.2.2]octane (DABCO; C6H12N2) and of 1-
azabicyclo[2.2.2]octane (quinuclidine; C7H13N) due to their widespread applications in
biotechnology and simple design [17]. The saturated bicyclic framework of these com-
pounds is found in natural physiologically active compounds [17]. In addition, these
surfactants display antibacterial [18] and antiviral [18] activity as well as improved sol-
ubility properties for hydrophobic dyes and drugs [17,19]. In this work, cationic NEs
composed of mono- and dicationic DABCO and quinuclidine surfactants produced and
supplied by Arbuzov Institute of Organic and Physical Chemistry of the FRC Kazan Scien-
tific Center of Russian Academy of Sciences (S1–S9) (Figure 1) have been used to exploit
their antimicrobial profile in drug delivery systems for ocular administration.
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Figure 1. Structures of cetyltrimethylammonium bromide (CTAB), and quaternary derivatives of quinuclidine (S3) and of
DABCO derivatives (S1, S2 and S4 to S9 surfactants) (Adapted from Ref. [17]).
The choice of oils, surfactants, cationic lipids, polymers, isotonizing agents that are
ophthalmically acceptable, is one of the most important steps to obtain a successful devel-
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opment of a stable and functional NE. The challenge is to have the potential to prolong the
precorneal residence time of the formulation and then improve the bioavailability and, at
the same time, it is essential to have an NE that is well tolerated, comfortable for patients
and without non-irritant consequences. In this way, to achieve the optimal formulations
for ocular delivery of TA, it is crucial to make a deep physicochemical characterization, i.e.,
measurement of droplets size, zeta potential, pH, osmolality, surface tension and viscosity.
The aim of this work was the development of a cationic NE with new surfactants to load TA
for ocular administration. Therefore, physicochemical characterizations were performed to
choose the lead NE formulations with the greatest potential for further biopharmaceutical
and tolerability studies.
2. Materials and Methods
2.1. Materials
Polysorbate 80 (Tween 80®) was purchased from Uniqema (Everberg, Belgium). Soy-
bean oil, CTAB (cetyltrimethylammonium bromide), glycerol and triamcinolone acetonide
(TA) were purchased from Sigma-Aldrich (Steinheim, Germany). Poloxamer 188 (Kolliphor
188) was purchased from BASF Schweiz AG (Kaisten, Germany). Cationic surfactants
(mono- and dicationic DABCO and quinuclidine) were synthesized at the Arbuzov Institute
of Organic and Physical Chemistry of the FRC Kazan Scientific Center of Russian Academy
of Sciences (Kazan, Russia) [17–19]. Ultra-purified water was obtained from Milli® Q Plus
system (Darmstadt, Germany), home supplied.
2.2. Methods
2.2.1. Factorial Design
The influence on the final properties of the NEs (mean particle size, polydispersity
index (PI) and zeta potential (ZP)), of the soybean oil concentration (internal phase) and
glycerol concentration (osmotic agent), as well as the amplitude of sonication, was evalu-
ated by using a 32 factorial design. This factorial design was composed of 3 variables that
were set at 2-levels each. For each variable, we studied the lower and higher values that
were represented by −1 and +1, respectively. The replication of the central point, repre-
sented by 0, was made three times in order to estimate the experimental error. The values
of each level were chosen based on literature research [13]. The NEs were produced, and
the data were analyzed using STATISTICA 7.0® (Statsoft, Inc., Tulsa, OK, USA) software.
An analysis of variance statistical test, ANOVA, was performed for each parameter to be
able to identify the implication of the effects and the interactions between them in the final
NEs. A p-value < 0.05 was considered statistically significant.
2.2.2. Preparation of Nanoemulsions
NEs were produced by dispersing the oil phase (composed of soybean oil, tween 80
and a cationic surfactant), heated at the same temperature, in an aqueous solution (com-
posed of glycerol, poloxamer 188 and water) using a probe sonication Qsonica 4435 Q55
Sonicator Microprobe, 1/4”, with 0.635 cm of tip diameter (Sonics Vibracell, Newtown,
CT, USA). The composition of each developed formulation is indicated in Table 1. Two
different amplitudes of sonication were studied, i.e., 60 or 100% of power output. Each
formulation studied was produced with a final volume of 30 mL. Briefly, both oil and
aqueous phases were heated up (~50 ◦C) in a water bath. The oil phase was dispersed in
the aqueous phase and was processed using a sonication probe for 5 min. After this, the
emulsion was transferred to an ice bath. The pre-formulation studies were performed using
cetyltrimethylammonium bromide (CTAB) (at 50 µg/mL, Table 1) as surfactant model,
once CTAB is a typical cationic surfactant [20]. The independent variables were defined
as: percentage of soybean oil, percentage of glycerol and the amplitude of the sonication
and dependent variables as: size, polydispersity index (PI) and zeta potential (ZP). Using
STATISTICA 7.0® software a 32 factorial design was implemented and 11 formulations, to
achieve the optimal formulation (Table 2), were made. After the pre-formulation studies
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using CTAB as the model surfactant, this cationic lipid was replaced by the synthesized
cationic surfactants (Figure 1) using their respective critical micelle concentration (CMC),
to produce nine formulations [17].
Table 1. Composition of the developed nanoemulsions containing CTAB or a cationic Surfactant 1 to 9 (S1 to S9, for structure














Pre-formulation 1.00 to 2.00 0.20 0.01 1.50 to 2.50 50 -
Formulation S1 2.00 0.20 0.01 1.50 - 1.00
Formulation S2 2.00 0.20 0.01 1.50 - 0.33
Formulation S3 2.00 0.20 0.01 1.50 - 0.80
Formulation S4 2.00 0.20 0.01 1.50 - 2.00
Formulation S5 2.00 0.20 0.01 1.50 - 3.00
Formulation S6 2.00 0.20 0.01 1.50 - 11.00
Formulation S7 2.00 0.20 0.01 1.50 - 4.00
Formulation S8 2.00 0.20 0.01 1.50 - 0.12
Formulation S9 2.00 0.20 0.01 1.50 - 0.08
Table 2. Experimental factorial design using CTAB as model surfactant.
Formulation Pattern Soybean Oil Glycerol Amplitude Soybean Oil(g)
Glycerol
(g) Amplitude
1 000 0 0 0 0.45 0.60 80
2 −++ −1 1 1 0.30 0.75 100
3 −−+ −1 −1 1 0.30 0.45 100
4 +−− 1 −1 −1 0.60 0.45 60
5 −+− −1 1 −1 0.30 0.75 60
6 +++ 1 1 1 0.60 0.75 100
7 000 0 0 0 0.45 0.60 80
8 000 0 0 0 0.45 0.60 80
9 −−− −1 −1 −1 0.30 0.45 60
10 ++− 1 1 −1 0.60 0.75 60
11 +−+ 1 −1 1 0.60 0.45 100
2.2.3. Physicochemical Characterization
Dynamic light scattering (DLS) was the method used to analyze the particle size
and polydispersity index (PI). This method records, in the microsecond time scale, the
scattered light intensity variation. In the DLS method, the particles in gas or liquid were
subjected to Brownian motions, and their movement can be perfectly described using the
Stokes-Einstein equation. In this study, NEs size and PI were determined in triplicate using
the Zetasizer Nano ZS (Malvern, UK). Values are presented as the mean of triplicate runs
per sample. For each measurement, the NE was diluted in Milli-Q water to an appropriate
concentration to avoid multiple scattering. The ZP is normally determined as the potential
difference between the medium of the dispersion and the fluid attached to the dispersed
particle. ZP measurements were performed by electrophoretic light scattering using a
Zetasizer Nano ZS (Malvern, UK). For analysis, samples were placed in a Flow Cell at
25 ◦C, diluted with Milli-Q water to a proper concentration. ZP was calculated using the
Helmholtz-Smoluchowski equation that was incorporated in the software system. Results
are presented as the mean of triplicate runs per sample.
2.2.4. Accelerated Stability Analysis
LUMiSizer® (Boulder, CO, USA) is a dispersion analyzer commonly used in the char-
acterization of substances separation in a mixture, i.e., sedimentation, creaming, flotation
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or consolidation. The simulated long-term physical stability of NE, without prior dilution,
was assessed by placing 1 mL of each sample in rectangular test-tubes (2 mm optical path)
and then subjected to rotor speed of 4000 rpm (centrifugal force 2300× g) at 25 ◦C, as
described in [21], a total of 850 profiles were obtained in intervals of 30 s. These assays
permitted differentiating between several mechanisms of instability at an accelerated and
known rate. Results were analyzed, using the SEPView® software (LUM GmbH, Berlin
Germany). The instability index was calculated by the software using the clarification at
each separation time divided by the maximum clarification [22]. The transmission profiles
are the result of the variation of transmitted light over time and space and give us the
information about the kinetics of the separation process and the velocity of migration of
particles (which is related to the particle size) [23,24].
2.2.5. Encapsulation Efficiency
In order to determine the efficiency of encapsulation, the NEs were submitted at
centrifugation with Amicon® Ultra Centrifugal Filters Ultracel (Millipore, Darmstadt,
Germany) for 15 min at 13,400× g to isolate the particles out of the suspension. The
free-TA was measured by the indirect method. The supernatant was measured using a
plate reader to determine the drug concentration. The standards of the calibration curve
were prepared by diluting the TA in Milli-Q water with 20% of ethanol to assure the total
dilution. The concentration of each standard of the calibration curve and the concentration
of the supernatant were measured in a BioTek Synergy HT plate reader at 240 nm (BioTek






where WTA is the mass of triamcinolone acetonide (TA) used for the production of the
loaded NEs and Ws is the mass of TA quantified in the supernatant. Centrifugal filter units
were used with a cut-off of 50 kDa, i.e., 50,000 nominal molecular weight limits (NMWL).
2.2.6. Surface Tension
The surface tension was assessed using KSV Sigma 70 Force Tensiometer (Helsinki,
Finland) that applies the Du Noüy ring detachment method taking into account the correc-
tion of Huh and Mason for interface distortion. The surface tension of NEs was measured
5 times at 37.3 ◦C, as described in [25].
2.2.7. Osmolality Assessment
The values of osmolality of the NEs were obtained using the EquipWescor Vapor
Pressure Osmometer VAPRO (Model 5520) (Logan, UT, USA). A 10 microliter of each
sample was placed into a solute-free paper disc in the sample holder. The measurement
initiates when the sample holder is pushed into the equipment. The measurement cycle
takes 80 s [25]. The results of Vapro displays in Standard International units, mOsm/kg.
2.2.8. Rheological Behavior
The rheology studies were performed on a rheometer Rheo Stress RS 100 (Haake
Instruments, Karlsruhe, Germany), applying the frequency sweep test. An oscillation
frequency sweep test was applied over a frequency range from 0 to 10 Hz. The storage
modulus (G′), loss modulus (G′′) and the complex viscosity (η*) of NE were determined as
a function of the frequency at constant stress amplitude of 5 Pa (linear viscoelastic region).
All experiments were performed at room temperature.
2.2.9. Stability of NEs in Simulated Tears
The stability of the formulations was tested in commercialized eye cleaning solutions
to anticipate whether droplets aggregation occurs upon eye administration. Two different
dilutions of NEs were tested on these solutions and the modifications on the physicochemi-
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cal properties were studied. One solution is saline solution sterile (sterile sodium chloride
0.9%) and another solution is a buffer with phosphates sterile and pH neutral (phosphate
solution 4.9%), normally used to neutralize acids and alkaline substances (neutral solution).
2.2.10. Morphology Analysis TEM
NEs were analyzed by transmission electronic microscopy (TEM). Samples were
mounted on a grid without staining and, after drying at room temperature, were examined
using the equipment TecnaiTM G2 Spirit BioTWIN (FEI Company, Hillsboro, OR, USA).
Image J Software (Version 1.47) (Bethesda, MD, USA) was used to analyze and measure the
NEs samples.
3. Results and Discussion
This work aimed to develop NEs able to deliver TA after topical administration in the
eye to treat or prevent AMD or other inflammatory and angiogenic ocular diseases. The
components of NEs altogether contributed to achieve long-term stable NEs for the delivery
of the poorly-water soluble TA. Soybean oil has been selected as a component of the inner
phase of NEs because it is a recognized non-irritating and biocompatible pharmaceutical
excipient [26]. Cationic quaternary ammonium surfactants (i.e., mono- and dicationic
DABCO and quinuclidine) are act as preservatives and contribute for the electrostatic
stabilization of the droplets due to the cationic charge at the interface [13]. A combination
of one cationic surfactant with a non-ionic surfactant (Tween 80) was used. Tween 80 is
described as a harmless, hydrophilic nonionic surfactant, and can cause reversible changes
in the permeability of the ocular surface. This non-ionic surfactant is used as a lubricant
in eye drops, promoting stereochemical stabilization of the inner oil droplets of the NEs
and contributes also with antimicrobial properties [27]. The use of cationic surfactants
in combination with non-ionic surfactants has already been recommended to improve
colloidal stability [28]. Poloxamer 188 (a non-ionic emulsifier) was used as a co-emulsifier
to reduce the size distribution [29]. Conjugation of tween 80 and poloxamer 188 is reported
to improve the spreading over the entire cornea-conjunctiva surface [30].
A factorial design of a new pharmaceutical formulation requires the identification of
the influencing parameters that will affect significantly the final product. The experimental
factorial design aims to study the effect of the different independent variables on the final
properties of the new pharmaceutical formulation. Factorial design is a statistical analysis
that provides a way to select the most optimal experimental conditions for the new phar-
maceutical formulation. Those conditions are, for example, different ratios of surfactants,
different concentrations of lipids, different conditions of production, i.e., different velocities
of sonication. This statistical analysis also estimates the influence of independent variables
on results of the dependent variables, i.e., mean particle size, polydispersity index (PI)
and zeta potential (ZP). In this study, these dependent variables were studied to deter-
mine the physicochemical properties of the NEs. A factorial design study was performed
to maximize the experimental efficiency using a minimum of experiments to obtain the
optimal NEs.
The challenge of the experimental design is the agreement with increasing number of
the factors and levels. The factorial design was composed of three variables that were set at
two-levels each (32). In this case, 11 formulations were made with different concentrations
of glycerol and soybean oil, unchanged concentration of CTAB (50 µg/mL) and different
amplitude of sonication to achieve the optimal formulation (Table 2). CTAB has been
selected as a cationic lipid/surfactant as it has been commonly used in the production of
cationic nanoparticles for ocular administration at a non-cytotoxic concentration [20,31].
NEs were stored at 4 ◦C. The mean particle size, the polydispersity index and the ZP were
measured on the day of production. The obtained results are shown in Table 3.
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Table 3. Response dependent variables and pH and osmolality of the three independent factors presented in Table 2 for all
the 11 produced NEs (Captions: z-Ave, mean particle size; PI, polydispersity index; ZP, zeta potential).





1 000 240.2 0.369 0.032 4.019 188
2 −++ 214.6 0.269 52.000 4.109 257
3 −−+ 216.9 0.262 47.600 3.953 151
4 +−− 162.1 0.203 63.600 4.030 154
5 −+− 207.6 0.282 38.200 4.839 238
6 +++ 262.9 0.328 10.600 4.146 277
7 000 242.0 0.329 0.035 4.314 211
8 000 210.0 0.258 0.003 4.174 219
9 −−− 189.2 0.213 −0.022 3.992 145
10 ++− 290.1 0.415 13.300 4.263 237
11 +−+ 264.0 0.319 15.600 4.186 239
Table 2 shows the amplitude used for each formulation as well as the concentration of
each lipid. The other constituents of the formulations that are not in this table are unaltered,
i.e., their concentrations are fixed. The column ‘pattern’ identifies the lower and higher
values represented by − that means −1 and + that means +1, respectively. The pattern
0 represents the central point that is the intermediate value of the variables. The ‘0’ was
represented in Table 2 three times because was made three formulations with these values
in order to estimate the experimental error of the assay. The results for the dependent
variables were described in Table 3. For every three dependent variables, analysis of the
variance (ANOVA) was performed using a confidence level of 95% confidence interval
(p-value = 0.05).
The obtained results were used to build the Pareto charts and the fitted surface
graphs for the different dependent variables. The response coefficients for the dependent
variables were studied for their statistical significance and the results are shown in Figure 2.
The t-value of effects are set on the Pareto chart. The variation of the low value to a
high value of the soybean oil concentration had a positive effect on the particle size,
i.e., t-value = 2.291333 (Figure 2a). Similarly, the interaction between the variation of the
soybean oil and glycerol from the lower to higher values had a positive effect on the
particle size, i.e., t-value = 1.683552. Likewise, the variation of amplitude from lower to
higher values had a positive effect on the particle size, i.e., t-value = 1.66228. The same
happened in the values of glycerol, i.e., t-value = 2.172815. As well as the interaction
between the variation of the soybean oil and the amplitude from the lower to higher values,
t-value = 0.6077806. If the t-value of effects set on the Pareto charts is less or equal to the
significant level (p < 0.05), this reveals that there is a statistically significant association
between the response variable and the term and statistical significance, meaning that there
is a good chance that we are right in finding that a relationship exists between two variables.
As it is possible to see in the Pareto charts, all the t-values are less than p = 0.05. On the
other hand, the interaction between the variation of the glycerol and amplitude from lower
to higher values had a negative effect on the particle size (t-value = −2.27614).
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The interactive effects between the different dependent variables studied were plotted
in thr e-dimensional respons surface graphs (Figure 2). In these surface respons charts,
the variations in the response values are in the Z-axis against the levels of the three
independent variables (glycerol in X-axis and soybean oil in Y-axis in the first graph,
amplitude X-axis and soybean oil in Y-axis in the second graph, amplitude in the X-axis
and glycerol in Y-axis in the last graph). The combination of high concentrations of glycerol
and soybean oil, as well as the combination of the high concentrations of soybean oil and
the amplitude increases the particle size to values above 300 nm while the best results
to the size particle are obtained when the combination of medium or low amplitude of
sonication with medium or lower concentr tion of glycerol. If in this last combination, any
variable has the higher value studied, the size particle achieves easily more than 250 nm.
A higher concentration of lipids leads to an increase of the viscosity of the formu-
lations, which promotes the particle agglomeration and then affects the mean particle
size [32]. The results of the polydispersity index (PI) (Figure 3) were also statistically
significant. The t-value obtained from the variation of the low value to a high value of
the concentrations of glycerol and soybean oil and the amplitude (1.995052, 1.605445 and
0.4366275, respectively) had a positive effect on the PI. The same was seen for the inter-
action between the concentration of glycerol and soybean oil, 0.9740152. Differently, the
t-value or the variation of the low values to high values of the interaction of concentratio
of glycerol and the amplitude showed a negative effect on the PI, −1.7801. Likewise, the
interaction between the soybean oil and the amplitude, −0.047021.
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Based on these findings, the amplitude that was selected as optimal to produce the
formulations and to proceed to the in vitro studies was the lower, 60. The three-dimensional
response surface graphs for the size and for the PI both showed that in all the interactions of
the amplitude with the differ nt concentrations of the surfactants, the low s value studied
for the amplitude present the smallest particle siz and rigin particles more homogeneous
due to the lowest PI. With these results, we decided to use de minor amplitude (−1) in the
next assays. According to this, the following surface response graphs (Figure 4) represents
that condition, i.e., with the amplitude value of 60 what is the influence of different
concentrations of soybean oil and glycerol in the mean size of the formulations, the PI
and ZP. In all of the surface response graphs (Figure 3), increasing glycerol concentration
creates NEs with higher mean size and with high values of PI and ZP values around zero.
As known, the ZP (i.e., the electrical char e at the NEs surface) reflects t e long-term
physical stability and show the t ndency for particles aggregation. Higher ZP values,
either positive or negative, mean that the formulations will ave greater long-term st bility
and long shelf-life [33]. The particle aggregation after production is less expect to occur
for charged particles with ZP > |20| mV, since there is electrostatic repulsion between
particles with the same electrical charge [34]. The NEs produced using CTAB are thus
reported to have higher stability according to the ZP, these are the NEs represented in the
Table 3 by the pattern −++, −−+, +−−, −+− (nanoemulsions 2, 3, 4 and 5, respectively).
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t ied (−1, i.e., 60) on the mean size (upper), olydispersity index (lower left) and on the zeta potential (lower right).
In addition to the surface response study described above, we used the LUMiSizer®
to analyze the shelf-life of the NEs using the space and time resolved extinction profiles.
Based on these profiles, demixing processes were measured regarding the clarification
velocity, the velocity of sedimentation and flotation of particles, the turbidity and separated
phase components—liquid or solid. This equipment uses the centrifugal sedimentation
approach to estimate the shelf-life of formulations at their original concentration and a fast
stability ranking. These est mations take minutes/hours i stead of days/months/years.
The ev lution of the transmission profiles along the time facilitates the nalysis of their
demixing behavior of tested formulations and their stability. It is possible to extrapolate
results to estimate the dispersion shelf-life of undiluted dispersions in minutes instead
of months or years [33]. Stable colloidal dispersions depict the formation of a flatbed
under a centrifugal field, while the aggregated particles usually show a step-profile [35].
Then, the centrifugal accelerations cause different sedimentation profiles and velocities
of formulations with heterogeneous size ranges. The instability phenomenon is related
to changes in the particle size distribution, due to their interaction, and to migration
particles [33]. As seen in Table 4, the formulation that howed a lower instability i dex was
the nanoemulsion 4 (0.214).
Table 4. Instability index of the formulations defined by factorial design.
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According to this approach, the most stable formulation was nanoemulsion 4 (+−−).
This result is in agreement with the surfaces responses obtained previously where the
minor amplitude and concentration of glycerol give us better results either in mean size, PI
and ZP values. The transmission profile of NE 4 is shown in Figure 5.
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Figure 5. Instability profile of nanoemulsion 4 on the day of production (day 0).
The instability profile of NE4 showed a very high level of clarification since the begin-
ning of the assay, which demonstrates that no migration or sedimentation occurred. After
these preliminary studies, nine NEs were produced replacing CTAB with the synthesized
su factants (as shown in Figure 1) using the composition of nanoemulsion 4 selected as
the optimal combination. All the formulations were monitored f r wo months taking into
account the mean size and the ZP. The results are shown in Figure 6.
Nanomaterials 2021, 11, x FOR PEER REVIEW 11 of 22 
 
 
7 0.917 1000–4000 
8 0.902 1 0–4 00 
9 0.914 1000–4  
10 0.87  1000–4  
11 0.912 1000–4000 
According to this approach, the most stable formulation was nanoemulsion 4 (+−−). 
This result is in agreement with the surfaces responses obtained previously where the 
minor amplitude and concentration of glycerol give us better results either in mean size, 
PI and ZP values. The transmission profile of NE 4 is shown in Figure 5. 
 
Figure 5. Instability profile of nanoemulsion 4 on the day of production (day 0). 
The instability profile of NE4 showed a very high level of clarification since the be-
ginning of the assay, which demonstrates that no migration or sedimentation occurred. 
After these preliminary studies, nine NEs were produced replacing CTAB with the syn-
thesized surfactants (as shown in Figure 1) using the composition of nanoemulsion 4 se-
lected as the optimal combination. All the formulations were monitored for two months 


















































Nanomaterials 2021, 11, 2758 12 of 22






    
    
Figure 6. Mean size and zeta potential (ZP) monitored over a period of 60 days of NEs produced with surfactant 1 to 9 (S1 
to S9) and with CTAB (used as model surfactant). Blue line represents the mean size and orange line the ZP. 
The most stable NEs were found to be those obtained with S2 and S7 (Figure 6). These 
NEs depict similar mean size and ZP profiles during the assay. Huge variations in size 
































































































































































































Figure 6. Mean size and zeta potential (ZP) monitored over a peri d of 60 days of NEs produced with surfactant 1 to 9
(S1 to S9) and with CTAB (used as model surfactant). Blu line repre ents the mean size and orang lin the ZP.
The most stable NEs were found to be those obtained with S2 and S7 (Figure 6). These
NEs depict similar mean size and ZP profiles during the assay. Huge variations in size
and ZP were recorded over time for the re aining surfactant-based NEs. The PI of NEs
Nanomaterials 2021, 11, 2758 13 of 22
produced with S2 and S7 was maintained around 0.21–0.23 over the 60 days, which ensures
that samples are able to keep the same physicochemical properties over time.
Osmolality translates the total concentration of solute in a solution, i.e., formulations
with a low solute concentration have a low osmolality and formulations with a high con-
centration of solutes have a high osmolality value [36]. In the case of ocular delivery of
drugs, formulations should not cause any discomfort upon administration, thus tolera-
bility of the formulations, pH and osmolality should be considered. The cornea reacts
upon changes in pH and osmolality, which can provoke reflex blinking and tearing. The
osmolality of the NEs produced with the nine surfactants and CTAB was studied over a
period of 60 days, stored at 4 ◦C. Table 5 shows the obtained results. All the formulations
have a hypotonic profile as the osmolality was lower than the physiologic values (approxi-
mately 289 mOsm/kg), which promotes fluid absorption. The use of hypotonic solutions
is highly recommended in, for example, dry eye syndrome due to higher values of tear
osmolality in this disease. There are no adverse effects reported upon the use of hypotonic
solutions [37,38].
Table 5. Osmolality (mOsm/kg) of NEs monitored over a period of 60 days stored at 4 ◦C. The pH values were recorded on
the day of production (day 0).
DAY 0 1 3 7 14 28 60
S1
Osmo.




































mOsm/kg 153 155 151 153 155 158 155
pH 4.030
These S2- and S7-based NEs were then selected for further studies. Figure 7 compares
the instability profiles obtained for S2, S7 and CTAB. Figure 7a,c shows profiles of samples
with a regular mean size distribution. These profiles are suggested by the symmetrical
spacing observed for the majority of the profile. Figure 7b shows an almost constant profile
over time. This profile presents the most homogeneous formulation, i.e., it shows higher
stability compared to S2 and CTAB. After this, and taking into account the stability of the
formulation, surfactants S2 and S7 were chosen for further studies. These formulations
were then produced to carry with the TA.
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Freshly prepared TA-loaded NEs (TA at 0.005%), the mean particle size and zeta
potential of samples were monitored for 28 days (Figure 8). Formulation 2 (F2) depicted
mean size as the nanoemulsion with the same composition but without TA (S2). In terms
of ZP, in the F2 there was an increase of the values in the first three days after production
and then stabilized to the same values that the S2. In the case of Formulation 7 (F7), the
mean size and ZP showed stable values over time. These values were significantly higher
when compared to the S7. For CTAB-based nanoemulsion containing TA, the mean size
values are more consistent over the same period of time. ZP values for this formulation
stabilized three days after production, as well as in F2 and F7.
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Figure 8. Mean size and zeta potential (ZP) recorded for the formulations F2, F7, CTAB-based
nanoemulsion containing TA, over a period of 28 days.
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The encapsulation efficiency was measured indirectly, by determining the amount of
free drug in the supernatant obtained by centrifugation (Table 6). Formulation F7 shows
the highest encapsulation efficiency for TA, whereas CTAB-based formulation depicted the
lowest encapsulation efficiency. For these three formulations, the variation of osmolality
was studied over a period of 28 days and the results are shown in Table 7.
Table 6. Encapsulation efficiency of Formulation F2, Formulation F7, CTAB-based NEs loaded with
triamcinolone acetonide.
Formulation F2 F7 CTAB-Based
Encapsulation Efficiency (%) 80.8 87.5 78.3
Table 7. Osmolality (mOsm/kg) of Formulation F2, Formulation F7, CTAB-based NEs loaded with triamcinolone acetonide
over a period of 28 days.
Formulation
Day
0 1 3 7 14 28
F2 169 171 177 170 176 174
F7 138 142 146 141 144 149
CTAB-based 136 139 150 143 147 152
The surface tension, a fundamental property of liquids surface, is defined as the energy,
or work, required to increase the liquid surface area due to intermolecular forces. Surface
tension is described as the ability to a surface of a portion of liquid be attracted by another
surface or portion of liquid [39]. Higher surface tension results from stronger interaction
between the molecules of the liquids’ surface with the neighboring molecules. As tempera-
ture decreases the surface tension increases due to more intermolecular bounds [39]. The
surface tension was obtained using KSV Sigma 70 equipment. The NEs were measured
five times at 37.3 ◦C. For F2 the surface tension was 24.32 ± 0.13 mN/m. In the case of F7,
the surface tension was 24.62 ± 0.05 mN/m. In the formulation prepared with CTAB, the
surface tension was 21.55± 0.29 mN/m. It should be taken into account that the tolerability
limits of osmolality for ophthalmic formulations range from 171 to 1711 mOsm/kg. Most
of the commercialized ophthalmic products, such as lubricants, have osmolality around
150–250 mOsm/kg [40]. F2 is the nanoemulsion depicting an osmolality value according to
the reference. The use of hypotonic formulations, such as F2, is required to decrease the
tear osmolarity from abnormally high values [41].
The rheology studies were performed using the frequency sweep test (Figure 9). An
oscillation frequency sweep test was applied over a frequency range from 0 to 10 Hz.
The storage modulus (G′), loss modulus (G′′) and the complex viscosity (η*) of NEs were
determined as a function of the frequency at constant stress amplitude of 5 Pa (linear
viscoelastic region). The G′ can be used as a measure of the elastic component of the
sample and the G′′ as the viscous component. In both formulations, F2 and F7, the elastic
modulus (G′) is dominant over the viscous modulus (G′′) and both of these are dependent
on frequency. The profiles of both formulations showed similar behavior in function
of frequency.
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The stability of the NEs was tested using an ocular formulation commonly commer-
cialized as a cleaning solution for the eyes. One solution is a sterile saline solution, and 
the other solution is a phosphate sterile buffer at neutral pH, normally used to neutralize 
acids and alkaline substances (neutral solution). These NEs were physicochemically char-
acterized during 24 h in terms of mean particle size and ZP in these fluids. The results 

















































Figure 9. Rheology studies of formulation F2 (left) and formulation F7 (right).
The analysis by transmission electron microscopy (TEM) is shown in Figure 10. The
a–c images were obtained on the day of production and d–f were obtained 28 days after
production. During this time, the samples were kept at 4 ◦C. NE droplets are clearly visible,
and the droplet size analysis was performed by the software of the TecnaiTM G2 Spirit
BioTWIN microscopic. The shape of the droplets was spherical in all formulations and the
appearance maintained similar after 28 days of production (Figure 10d–f).




Figure 9. Rheology studies of formulation F2 (left) and formulation F7 (right). 
The analysis by trans ission electron icroscopy (TE ) is sho n in Figure 10. The 
a–c i ages ere obtained on the day of ro uction and d–f ere obtai ed 28 ays after 
pro cti . ri  t is ti e, t e sa ples were kept at 4 °C. NE droplets are clearly visi-
ble, and the droplet size nalysis was performed by the software of the TecnaiTM  irit 
BioT I  icr sc i . The sha e of the droplets as spherical i  all for lati s a  t e 
appearance aintained si ilar after 28 ays of r cti  ( i r  . 













Figure 10. Images obtained using a transmission electron microscopy. F2 at day 0 (a) and at 28 days after production (d). 
F7 at day 0 (b) and at day 28 days after production (e). CTAB at day 0 (c) and at day 28 after production (f). 
The stability of the NEs was tested using an ocular formulation commonly commer-
cialized as a cleaning solution for the eyes. One solution is a sterile saline solution, and 
the other solution is a phosphate sterile buffer at neutral pH, normally used to neutralize 
acids and alkaline substances (neutral solution). These NEs were physicochemically char-
acterized during 24 h in terms of mean particle size and ZP in these fluids. The results 

















































Fig re . I a s t i i tr ission electron microscopy. F2 at day 0 (a) and at 28 days after production (d). F7
at day 0 (b) and at day 28 days after p oduction (e). CTAB at day 0 (c) and at day 28 after p oduction (f).
The stability of the Es as tested using an ocular formulation commonly commer-
cialized as a cleaning solution for the eyes. One solution is a sterile saline solution, and the
other solution is a phosphate sterile buffer at neutral pH, normally used to neutralize acids
and alkaline substances (neutral solution). These NEs were physicochemically character-
ized during 24 h in terms of mean particle size and ZP in these fluids. The results obtained
were compared with the original NEs (results in dashed line, Figure 11). In both dilutions,
in all the NEs, the ZP was maintained almost the same during the assay. However, in all
Nanomaterials 2021, 11, 2758 18 of 22
the profiles, the ZP of the NEs diluted in the sterile saline solution is significantly lower
when compared to the original NE.
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Figure 11. Zeta potential variation recorded on day zero and 24 h after production of Es, determined in sterile saline
solution, for two distinct dilutions at 1:1 (left-hand side panels, (a–c ) and at 1:3 (right-hand side panels, (d–f ). Blue line
refers to: mean particle size of NEs after dilution in the di ferent solutions (continuous line) and mean particle size of
original Es (dashed line); orange line refers to: ZP of NEs after dilution in the different solutions (continuous line) and ZP
of original NEs (dashed line).
The more concentrated F2 (Figure 11a) shows initially an increase in the mean particle
size when in contact with the saline solution comparing to the original NE; however, the
mean particle size decreases dramatically to values similar to the original F2 NE. Whereas,
for the more diluted F2 (Figure 11d) the behavior is exactly the opposite when in contact to
the saline solution there was a decrease in the mean particle size and after this, there was
an increase in the mean particle size to values ≈ 290 nm.
The F7/saline solution more concentrated (Figure 11b) did not show a significant
difference in the mean particle size when compared to the F7 original NE during the assay.
F7 more diluted (Figure 11e) in saline solution showed the same mean particle size in all
the assay but this value is higher when compared to the original F7 NE.
The CTAB/saline solution more concentrated had the same mean particle size in all the
assay, but this value is higher when compared to the original CTAB NE. For CTAB/saline
solution more diluted, there was an increase if the mean particle size during the assay. In
the beginning, the mean particle size was similar to the original CTAB NE and during the
assay this value decreased significantly. The results for the dilution in the sterile phosphate
buffer at neutral pH are shown in Figure 12.
















Figure 12. Behavior of NEs in sterile phosphate buffer at neutral pH for two different dilutions, at 1:1 (left-hand side 
panels, (a–c)) and at 1:3 (right-hand side panels, (d–f)). Blue line refers to: mean particle size of NE after dilution in the 
different solutions (continuous line) and mean particle size of original NEs (dashed line); orange line refers to: ZP of NEs 
after dilution in the different solutions (continuous line) and ZP of original NEs (dashed line). 
Similar to the dilutions in the sterile saline solution, the ZP was maintained almost 
the same during the assay. Nevertheless, in all the profiles, the ZP of the NEs diluted in 
sterile phosphate buffer at neutral pH is significantly lower when compared to the origi-
nal NE. 
The F2 (dilution 1:1) (Figure 12a) initially shows an increase in the mean particle size 
when in contact with the sterile phosphate buffer at neutral pH comparing to the original 
F2 NE, and during the assay, the mean particle size continues to increase. The F2 more 
diluted (1:3) (Figure 12d) behavior is exactly the same in the beginning, i.e., increase the 
mean particle size when in contact with the sterile phosphate buffer at neutral pH and this 
value is maintained during the assay. 
The F7/buffer with phosphates sterile at neutral pH at 1:1 dilution (Figure 12b) 
showed a slight increase in the mean particle size when compared to the F7 original NE 
during the assay. F7 more diluted (Figure 11e) in sterile phosphate buffer at neutral pH 
showed the same mean particle size in all the assay and this value is slightly lower than 
the reference. 
The CTAB/buffer with phosphates sterile and pH neutral at 1:1 dilution had the same 
mean particle size and ZP in all the assay. For CTAB/buffer with phosphates sterile and 
pH neutral more diluted, there was an increase of the mean particle size during the assay. 
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solutio s (continuous line) and m an particle size of original NEs (dashed line); orange line r fers to: ZP f NEs after
dilution in the different solutions (continuous line) and ZP of original NEs (dashed line).
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when in contact with the sterile phospha e buffer at neutral pH comparing to the original
F2 NE, and during the assay, the mean particl size continues t increase. The F2 more
diluted (1:3) (Figure 12d) behavior is exactly th ame i the begin ing, i. ., increase th
mean particle size when in contact with the sterile phosphate buffer at eutral pH and this
value is maintained during the ssay.
The F7/buffer with phosphates sterile at neutral pH at 1:1 dilution (Figure 12b) showed
a slight increase in the mean particle size when compared to the F7 original NE during the
assay. F7 more diluted (Figure 11e) in sterile phosphate buffer at neutral pH showed the
same mean particle size in all the assay and this value is slightly lower than the reference.
The CTAB/buffer with phosphates sterile and pH neutral at 1:1 dilution had the
same mean particle size and ZP in all the assay. For CTAB/buffer with phosphates sterile
and pH neutral more diluted, there was an increase of the mean particle size during the
assay. However, the ZP is the same during the 24 h. There was an enormous increase
in the osmolality values of the NE when dissolved in the ocular formulation commonly
commercialized as cleaning solutions of the eye (Table 8). The values of the osmolality
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in all the concentrations and in both solutions despite the increase were in the gap of
the permissible osmolality values. The sterile saline solution has 279 mOsm/kg and the
sterile buffer with phosphates and neutral pH has 704 mOsm/kg. As shown in Table 8, an
increase in the osmolality was recorded upon dilution for the formulations. However, when
compared to our developed NEs, the use of the saline solution and/or phosphate buffer
does not contribute to improve the quality of the formulations for ocular administration;
indeed, the increased osmolality seen with these commercial solutions, in comparison to
our optimal formulations loaded with triamcinolone acetonide (Table 7), may induce a
cytotoxic effect in the eye. Dutesco et al. showed that hypertonic formulations change the
tear osmolarity and consequently induce ocular inflammation [37].
Table 8. Osmolality of the diluted formulation in different solution at different ratios.
Formulation
NEs in Sterile Saline Solution NEs in Sterile Phosphate Buffer at Neutral pH
(1:1 Dilution) (1:3 Dilution) (1:1 Dilution) (1:3 Dilution)
F2 204 243 479 601
F7 200 244 464 602
CTAB-based 236 261 481 606
4. Conclusions
Newly synthesized quaternary derivatives of 1,4-diazabicyclo[2.2.2]octane (DABCO)
and quinuclidine surfactants were the compounds used to formulate long-term stable
nanoemulsions. Nanoemulsions revealed optimal physicochemical properties for the load-
ing of triamcinolone acetonide intended for ocular administration. In the treatment of
age-related macular degeneration, triamcinolone acetonide is one of the first pharmacologic
drugs used that is only applied as intravitreal injections. Triamcinolone acetonide is a syn-
thetic corticosteroid that is well tolerated by ocular tissues. The developed nanoemulsions
loading triamcinolone acetonide showed long-term stability and physicochemical charac-
teristics that are aligned with the requirements for ocular administration. Formulation F2
and formulation F7 presented a monodispersed population, i.e., higher stability comparing
to the others and in the future, it will be recommended to conduct further studies in order
to test their behavior in vitro and in vivo assays.
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